PHARMACEUTICAL COMPOSITIONS AND METHODS FOR EFFECTING DOPAMINE RELEASE

摘要

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo¢2.2.1!heptane, a 1-aza-2-(3-pyridyl)bicyclo¢2.2.2! octane, a 1-aza-2-(3-pyridyl)bicyclo¢3.2.2!nonane, a 1aza-7-(3-pyridyl) bicyclo¢2.2.1!heptane, a 1-aza-3-(3-pyridyl)bicyclo¢3.2.2!nonane, or a 1-aza-7-(3-pyridyl)bicyclo¢3.2.2!nonane.